Understanding the Synthesis and Application of 4-Pyridin-4-ylbutanoic Acid Hydrochloride
The complex landscape of organic synthesis often hinges on the availability and understanding of key intermediate compounds. 4-Pyridin-4-ylbutanoic Acid Hydrochloride, identified by CAS 71879-56-6, is one such molecule that plays a pivotal role in the pharmaceutical sector. NINGBO INNO PHARMCHEM CO.,LTD., a prominent chemical manufacturer, offers this compound and insights into its synthesis and application, particularly its use as a precursor to Tirofiban Hydrochloride.
The synthesis of 4-Pyridin-4-ylbutanoic Acid Hydrochloride involves multi-step organic reactions, requiring precise control over reaction conditions to achieve the desired purity and yield. While specific proprietary synthesis routes may vary, the general pathways often involve functionalization of pyridine derivatives and subsequent chain elongation and salt formation. The product’s characteristics, such as its white powder appearance and a minimum purity of ≥95%, are critical quality indicators. NINGBO INNO PHARMCHEM CO.,LTD. leverages advanced synthetic techniques to consistently deliver this compound to the market.
The primary application of 4-Pyridin-4-ylbutanoic Acid Hydrochloride is its critical function as a building block in the synthesis of Tirofiban Hydrochloride. Tirofiban, a glycoprotein IIb/IIIa inhibitor, is a cornerstone in the treatment of patients with acute coronary syndromes, preventing platelet aggregation and reducing the risk of heart attack. The demand for this intermediate is directly linked to the global demand for antiplatelet therapies. For companies looking to purchase this essential chemical, understanding the expertise of NINGBO INNO PHARMCHEM CO.,LTD. as a reliable manufacturer in China provides confidence in obtaining a quality product that supports their drug development pipeline.
Perspectives & Insights
Molecule Vision 7
“The primary application of 4-Pyridin-4-ylbutanoic Acid Hydrochloride is its critical function as a building block in the synthesis of Tirofiban Hydrochloride.”
Alpha Origin 24
“Tirofiban, a glycoprotein IIb/IIIa inhibitor, is a cornerstone in the treatment of patients with acute coronary syndromes, preventing platelet aggregation and reducing the risk of heart attack.”
Future Analyst X
“The demand for this intermediate is directly linked to the global demand for antiplatelet therapies.”